![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Friday, March 07, 2014 9:17:34 PM
The timing is a bit off, so the world has to wait.
If the Pseudo-progression enrollment didn't start until 2011 or so, then it may be the 72 spaces they added to the trial are for the them.
Do some very simple math.
Ultimately 240 in the main body.
Ultimately 112 events required for final analysis
66 required for 1st interim analysis.
72 in the alternative group (pseudo-progression)
Ultimately 33 events "desired" for final analysis.
19 "desired" for 1st interim analysis.
If you met the primary endpoint in the main body, the pseudo-progression group is not an afterthought. They are just as important, and you would want to analyze the results before you unblind the trial. You would not want to neglect this very important group, and even though they are analyzed separately, ultimately you would want to also determine how both groups did as a whole.
If you were simply going to continue the main body of the trial, you could simply do that and analyze the pseudo-progression group at the second interim analysis for the primary group. You would not wait for the pseudo-progression minimum events at the 1st interim analysis in this situation.
This would explain why they are telling us efficacy data analysis is pending.
Finally, there would be simply no reason to halt the trial for futility at the 1st interim unless the results on the primary group were showing a statistical detriment (which would be a safety issue) to the patients. Thus the safety continuation is more meaningful at the 1st interim than perhaps any other time when you have a very safe treatment.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM